| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
SRX3305 (0.1-100 μM; 72 h) inhibited the proliferation of B-cell non-Hodgkin lymphoma (B-NHL) cell lines with an average IC50 value of 1.38 μM[1]. SRX3305 (0.1-100 μM; 72 h) reduced the proliferation of diffuse large B-cell lymphoma (DLBCL) cells, with an IC50 value of approximately 290 nM in OCI-LY3 cells and approximately 920 nM in SU-DHL-6 cells[1]. SRX3305 (0.5-2 μM; 24-48 h) induced apoptosis in HG-3 and OSU-CLL cells in a dose-dependent manner[1]. SRX3305 (0.5–2 μM; 4 h) inhibited key BCR survival signaling pathways in OSU-CLL, MEC-1, and MEC-2 cell lines [1]. SRX3305 (0.16–5 μM; 48 h) inhibited the survival and proliferation of primary malignant B cells isolated from Eμ-TCL1 (CLL model) and Eμ-Myc/TCL1 mice [1]. SRX3305 (0.5–2 μM; 48 h) disrupted matrix survival support and chemokine-induced migration in CLL cells [1]. SRX3305 (0.5–2 μM; 48 h) overcame tumor microenvironment (TME)-induced survival signaling in MEC-1 cells [1]. SRX3305 (0.1–100 μM; 72 h) was active against ibrutinib-resistant HG-3 cells [1]. SRX3305 (10 nM-100 μM; 48 hours) had an IC50 of 1 nM in Mino cells, 58 nM in JeKo-1 cells, 1.1 μM in Granta cells, 1 μM in JeKo-1 BTK C481S mutant cells, and 47 nM in Mino BTK C481S mutant cells[2]. SRX3305 (0.375-2 μM; 48 hours) showed very low toxicity to healthy donor peripheral blood mononuclear cells (PBMCs) or surrounding healthy stromal cells, and also showed very low toxicity to healthy donor B cells[2]. SRX3305 (0.1-10 μM; 48 hours) had antitumor activity against primary Eμ-Myc tumor samples[2]. SRX3305 (0.01-0.5 μM; 1 hour) blocked the activation of BTK and AKT[2]. SRX3305 (0.01–1 μM; 1 h) showed superior efficacy in mantle cell lymphoma (MCL) and ibrutinib-resistant MCL cells [2]. SRX3305 (1 h) still inhibited the phosphorylation of BTK and AKT in Mino cells after inhibitor washout [2]. SRX3305 (0.5–2 μM; 24 h) inhibited the proliferation of JeKo-1 and Mino cells by inducing S/G2 phase cell cycle arrest and promoting apoptosis [2].
|
|---|---|
| References |
|
| Molecular Formula |
C22H20N2O5S
|
|---|---|
| Molecular Weight |
424.47
|
| CAS # |
2409965-28-0
|
| Appearance |
Typically exists as solids at room temperature
|
| SMILES |
O=C1C=C(N2CCOCC2)OC3=C1SC=C3C4=CC5=C(OCCN5C(C=C)=O)C=C4
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3559 mL | 11.7794 mL | 23.5588 mL | |
| 5 mM | 0.4712 mL | 2.3559 mL | 4.7118 mL | |
| 10 mM | 0.2356 mL | 1.1779 mL | 2.3559 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
